-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Lysogene disclosed Thursday that one patient in the Phase II/III AAVance study died and is undergoing gene therapy LYS-SAF302 to treat type IIIA adhesive polysaccharose storage disorder (MPS IIIA).
Lysogene's share price fell as much as 19 percent on the news, and the cause of death is not yet known, but there is no evidence linking the death to LYS-SAF302.
LYS-SAF302, a gene therapy for MPS IIIA developed by Lysogene, is a gene therapy mediated by adenopathic viruses (AAVs) that aims to replace defective SGSH genes by delivering functional SGSH genes through AAV.
three elements of research gene therapy (LYS-SAF302) for MPS IIIA are: vector: AAVrh10 initiater: CAG delivery gene: complete SGSH gene Lysogene said it would study the remaining 18 patients "strictly in accordance with the research program."
picture source: